Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study

Arthritis and Rheumatism

Volumn 41, Issue 4, 1998, Pages 670-677

  Wigley, Fredrick M ^a,s   Korn, Joseph H ^b   Csuka, M E ^c   Medsger Jr , Thomas A ^d   Rothfield, Naomi F ^e   Ellman, Michael ^f   Martin, Richard ^g   Collier, David H ^h   Weinstein, Arthur ⁱ   Furst, Daniel E ^j   Jimenez, Sergio A ^k   Mayes, Maureen D ^l   Merkel, Peter A ^m   Gruber, Barry ⁿ   Kaufman, Lee ⁿ   Varga, John ^o   Bell, Patrice ^p   Kern, John ^p   Marrott, Pran ^p   White, Barbara ^q   Simms, Robert W ^b   Phillips, Andree C ^m   Seibold, James R ^r   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF CONNECTICUT   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g MICHIGAN STATE UNIVERSITY   (United States)

^h DENVER HEALTH MEDICAL CENTER   (United States)

ⁱ NEW YORK MEDICAL COLLEGE   (United States)

^j BENAROYA RESEARCH INSTITUTE   (United States)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

^l WAYNE STATE UNIVERSITY   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ STONY BROOK UNIVERSITY   (United States)

^o UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^p BAYER PHARMA AG   (Germany)

^q UNIVERSITY OF MARYLAND   (United States)

^r ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^s JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; ULCER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; ILOPROST; MALE; MIDDLE AGED; NAUSEA; PLACEBOS; RAYNAUD DISEASE; RECURRENCE; SCLERODERMA, SYSTEMIC; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 0031947367     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I     Document Type: Article

References (28)

1. Wigley FM, Flavahan NA. Raynaud's phenomenon. Rheum Dis Clin North Am 1996;22:765-81.
2. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980;59:393-408.
3. Pearson JD. The endothelium: its role in scleroderma. Ann Rheum Dis 1991;50:866-71.
4. Belch JF, Newman P, Drury JK, Capell H, Leiberman P, James WB, et al. Successful treatment of Raynaud's syndrome with prostacyclin. Thromb Haemost 1981;45:255-6.
5. Belch JJ, Drury JK, McKenzie F, Capell H, Leiberman P, Forbes CD, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial. Lancet 1983;1:313-5.
6. 2). Br J Dermatol 1982;106:81-9.
7. Yardumian DA, Isenberg DA, Rustin M, Belcher G, Smith ML, Dowd PM, et al. Successful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988;27:220-6.
8. McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43-7.
9. Kyle MV, Belcher G, Hazelman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992;19:1403-6.
10. Wigley FM, Seibold JR, Wise RA, McClosky DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-13.
11. Torley HI, Madhok R, Capell HA, Brouwer RM, Maddison PJ, Black CM, et al. A double blind, randomized, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue disease. Ann Rheum Dis 1991;50:800-4.
12. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TK, et al. Comparison of intravenous infusion of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomized study. BMJ 1989;298:561-4.
13. Rademaker M, Thomas RH, Provost G, Beacham JA, Cooke ED, Kirby JD. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J 1987;63:617-20.
14. Watson HR, Belcher G. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon. Ann Rheum Dis 1991;50:359-61.
15. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujalu G, Medsger TA, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
16. Wise RA, Wigley FM. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon. J Rheumatol 1994;21:80-3.
17. Tsukamoto H, Nagasawa K. Successful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E1 analogue [letter]. Br J Rheumatol 1991;30:317.
18. Lau CS, Belch JJF, Madhok R, Cappell H, Herrick A, Jayson M, et al. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Clin Exp Rheumatol 1993;11:35-40.
19. Vayssairat M. Controlled multicenter double blind trial on an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. J Rheumatol 1996;23:1917-20.
20. Belch JJF, Capell HA, Cooke ED, Kirby JDT, Lau CS, Madhok R, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 1995;54:197-200.
21. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
22. Van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Inst Int Stat 1960;37:351-61.
23. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day; 1975.
24. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
25. Varga J, Jimenez SA. Modulation of collagen gene expression: its relation to fibrosis in systemic sclerosis and other disorders. Ann Intern Med 1995;122:60-2.
26. Casciola-Rosen L, Wigley FM, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997;185:71-9.
27. Coffman JD, Clement DL, Creager MA, Dormandy JA, Janssens MML, McKendry RJR, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989;87:264-8.
28. Seibold JR, Furst DE, Clements P. Why everything (or nothing) seems to work in the treatment of scleroderma. J Rheumatol 1992;19:673-6.